SCHEMBL4638239

SCHEMBL4638239

NC(=O)NS(=O)(=O)c1ccc(C(N)=O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.59
MMP2 P08253 1/20 0.55
MMP14 P50281 1/20 0.55
CA1 P00915 3/20 0.53
CA9 Q16790 2/20 0.53
CA12 O43570 1/20 0.53
CA14 Q9ULX7 1/20 0.53
FLT1 P17948 4/20 0.50
FLT4 P35916 4/20 0.50
KDR P35968 4/20 0.50
POLB P06746 2/20 0.49
KAT6A Q92794 1/20 0.48
TSHR P16473 2/20 0.47
DHFR P00374 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
KMT2A Q03164 1/20 0.46
F2 P00734 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2028416 0.85 CA2 (0.55) CA2MMP2MMP14CA1CA9
SCHEMBL4071822 0.85 SMN1; SMN2 (0.68) CA2CA1CA9CA12CA14
SCHEMBL12190345 0.82 CA2 (0.61) CA2MMP2CA1CA9CA12
Sulfacarbamide SCHEMBL154846 0.82 TSHR (0.69) CA2MMP2MMP14CA1CA9
SCHEMBL376340 0.80 MEN1 (0.73) CA2CA1CA9FLT1FLT4
SCHEMBL7264925 0.80 FLT1 (0.65) CA2MMP2CA1CA9CA12
SCHEMBL170426 0.80 CA1 (0.59) CA2MMP2CA1CA9CA12
SCHEMBL1870821 0.80 CA2 (0.59) CA2CA1CA9CA12CA14
SCHEMBL12187037 0.80 CA1 (0.66) CA2MMP2MMP14CA1CA9
SCHEMBL4773166 0.80 CA1 (0.59) CA2MMP2MMP14CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP claimed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO claimed
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP disclosed
US-8367667-B2 Pyrrole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2013-02-05 US disclosed
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2011-12-08 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP disclosed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP disclosed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 CA2 1737/4885MMP2 3273/4885MMP14 3530/4885
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 CA2 1737/4885MMP2 3273/4885MMP14 3530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.